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Abstract Integrin K4L1 is a major leukocyte adhesion receptor
that is a key target for the development of anti-inflammatory
therapeutics. With the dual long-term goals of developing a
reagent for use in high-throughput inhibitor screening assays and
for crystallisation trials and subsequent structure determination,
we have generated a recombinant soluble K4L1 receptor. Both
subunits were truncated prior to the transmembrane domains by
site-directed mutagenesis and expressed using baculovirus
infection of insect cells. The molecular weights of the recombi-
nant subunits were as expected for post-translationally unmodi-
fied protein. In addition, as observed for the native subunit, a
proportion of the K4 subunit was proteolytically processed into
two fragments. ELISA and solid phase ligand-binding assays
were performed to investigate the folding and functionality of the
soluble integrin. The data suggest that the receptor was correctly
folded and that it bound recombinant ligands with similar
kinetics to the native molecule.
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1. Introduction
Integrin K4L1 is a major leukocyte adhesion receptor that
binds primarily to the cell surface immunoglobulin vascular
cell adhesion molecule-1 (VCAM-1) and the extracellular ma-
trix protein ¢bronectin [1]. Perturbation of K4L1 function in
animal models of in£ammation using either monoclonal anti-
bodies or ligand mimetic peptides has indicated a major role
for this receptor in conditions such as asthma [2], rheumatoid
arthritis [3] and atherosclerosis [4] and made it a key target for
the development of anti-in£ammatory therapeutics (reviewed
in [5]). The development of such therapeutic agents is cur-
rently hampered by the lack of tertiary structure information
for K4L1, and by the lack of a reagent to permit high-through-
put drug screening. One solution to these problems would
be the generation of a recombinant soluble form of the recep-
tor.
All integrins are heterodimeric proteins consisting of non-
covalently-associated K and L subunits [6]. Since both sub-
units possess a single transmembrane domain, truncation of
each would be needed to generate the soluble receptor. In
addition, some integrins, including K4L1 [7], exhibit only
weak inter-subunit association, suggesting that soluble recep-
tors may dissociate into their component subunits. Despite
these potential di⁄culties, in recent years, a number of trun-
cated integrins have been produced using both eukaryotic and
insect cell hosts. All of the soluble truncated integrins have
been produced by deletion or replacement of the integrin
transmembrane and cytoplasmic domains. Using a baculovi-
rus expression system, a soluble KIIbL3 integrin was expressed
using Sf9 cells which consisted of the heavy chain of the KIIb
subunit and a shortened L3 subunit truncated before the cys-
teine-rich repeats [8]. The soluble KIIbL3 produced was a
divalent cation-dependent complex which was functionally ac-
tive in binding its ligand ¢brinogen with similar a⁄nity to
full-length KIIbL3 puri¢ed from platelets. Rotary shadowing
of the full-length and soluble KIIbL3 revealed similar struc-
tures with a globular head and two tails, which were short-
ened in the soluble integrin [8]. Similar KVL3 and KVL5 in-
tegrin constructs have been expressed using a baculovirus
expression system [9,10], while soluble KIIbL3 and KVL3
integrins and an K8L1-alkaline phosphatase chimera have
been produced using mammalian COS and HEK293 cells
[11^13].
To resolve potential problems with inter-subunit association
during the production of soluble integrins, soluble K3L1 in-
tegrin has been produced with the cytoplasmic and transmem-
brane domains replaced by the Jun and Fos dimerisation mo-
tifs [14]. The chimeric integrin was produced using a
Drosophila expression system and subunit association and
processing were observed. The soluble K3L1 bound to its li-
gands, invasin and laminin-5. Soluble KVL5 has since been
expressed using the same Jun-Fos tail dimerisation method,
also in insect cells [15]. A majority of the soluble integrins that
have been reported were puri¢ed on a ligand or peptide ligand
mimetic column (an RGD column for KIIbL3 [8,9,11] and
invasin for K3L1 [14]). The only published puri¢cation using
an epitope tag was for the K8L1-alkaline phosphatase chimera
which was puri¢ed on a nickel column utilising a His tag
added to the K8 subunit [12].
With the dual long-term goals of developing a reagent that
might be used for high-throughput inhibitor screening assays
and that might serve as a starting point for crystallisation
trials and subsequent structure determination, we report
here the generation of a recombinant soluble K4L1 receptor
(rsK4L1). The K4 and L1 subunits were truncated prior to the
transmembrane domains by site-directed mutagenesis and
expressed in insect cells. An epitope tag was added at the
C-terminus of the K4 subunit to aid isolation by immunoaf-
¢nity chromatography.
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2. Materials and methods
2.1. Antibodies
The antibodies used in this study were: the mouse anti-human L1
monoclonals 8E3 [16], 12G10 [16], 15/7 (from Ted Yednock, Athena
Neurosciences, Seattle, WA, USA), JB1B (from Serotec, Oxford,
UK), K20, 4B4 (both from Coulter Electronics, Luton, UK), TS2/
16 (from Francisco Sanchez-Madrid, Hospital de la Princesa, Madrid,
Spain), the rat anti-human L1 monoclonals 13 (from Ken Yamada,
NIH, Bethesda, MD, USA) and 9EG7 (from Dietmar Vestweber,
University of Munster, Germany), the mouse anti-human K4 mono-
clonals 8F2 (from Chikao Morimoto, Dana-Farber Cancer Institute,
Boston, MA, USA), HP2/1, HP1/2, HP1/3 (all three from Francisco
Sanchez-Madrid), GG5/3 and 44H6 (both from Ted Yednock), and
the mouse anti-Ty epitope monoclonal BB2 (from Jayne Brookman,
University of Manchester). Non-immune mouse and rat IgG were
purchased from Sigma (Poole, Dorset, UK).
2.2. Mutagenesis of integrin subunit cDNAs and transfer vector
construction
Full-length cDNA constructs encoding the human K4 (in pBlue-
script) and L1 (in pcDNA3) integrin subunits were kindly donated
by Martin Hemler (Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA, USA) and Erkki Ruoslahti (Burnham Institute,
La Jolla, CA, USA), respectively. A KpnI^XbaI fragment of K4, which
contained the region to be targeted for mutagenesis, was subcloned
into pUC118. The L1 cDNA was excised by EcoRI digestion and
subcloned into pUC118. A shortened L1 construct was produced by
removal of an internal BglII fragment and religation. CJ236 Escheri-
chia coli cells were transformed with the pUC118 constructs and in-
fected with M13 phage to produce single-stranded DNA (ssDNA).
The ssDNA was isolated and was used for site-directed mutagenesis
according to the method of Kunkel [17].
The mutagenic oligonucleotide 5P GCT ACT TGA AAT AAT
CAC TAT GGT CTA ATC AAG GGG ATC TTG GTT TGT
ATG AAC TTC ATA ACG TTT GGG TCT TTG ATG ATG 3P
was used to mutate the K4 cDNA to contain a 10 amino acid epitope
tag and stop codon (underlined sequence) two amino acids 5P to the
predicted transmembrane domain. The epitope tag was designed from
a sequence of the Ty1 surface protein of the virus-like particle of
Saccharomyces cerevisiae for which a monoclonal antibody had
been produced [18]. It was considered unlikely that this monoclonal
antibody would cross-react with proteins of other species. The full-
length K4 cDNA was reconstructed within the original pBlueScript
vector following KpnI^XbaI digestion of the mutant fragment and
religation. Mutant K4 was excised with SalI and XbaI and subcloned
into the pFASTBAC transfer vector (Gibco-BRL, Paisley, UK).
The mutagenic oligonucleotide 5P GGA ATG ATG TCT TAA
CCA GTG GG 3P was used to mutate the L1 cDNA to contain a
stop codon (underlined sequence) two amino acids 5P to the encoded
predicted transmembrane domain. The excised L1 BglII cDNA frag-
ment was reinserted into the mutated L1 cDNA and the ends were
sequenced. The L1 cDNA was then subcloned into the original
pcDNA3 vector, and re-excised with KpnI and XhoI for subcloning
into the pFASTBAC transfer vector.
2.3. Translocation and bacmid puri¢cation
The transfer vector containing the two mutated cDNA constructs
was transformed into DH10BAC E. coli cells, which harbour a copy
of the baculovirus genome (bacmid), according to the manufacturer’s
instructions (Gibco-BRL, Paisley, UK). Translocation of the vector
region containing the encoded subunits and virus promoters into the
bacmid was then induced. Cells containing recombinant bacmid were
identi¢ed as white colonies due to disruption of an encoded LacZ
cassette within the bacmid. Recombinant bacmid was then isolated
and analysed by agarose gel electrophoresis to con¢rm the presence of
bacmid DNA.
2.4. Sf9 cell transfection and recombinant virus production
Isolated recombinant bacmid was transfected into Sf9 insect cells by
lipofection to produce recombinant virus. 1U106 Sf9 cells were seeded
into 35 mm plates and left to attach for 1 h. 5 Wl of recombinant
bacmid DNA was mixed with 100 Wl of Grace’s medium and a second
mixture of 6 Wl of Cellfectin reagent (Gibco-BRL, Paisley, UK) in 100
Wl Grace’s medium was prepared. The two mixtures were combined
and gently mixed before incubating for 45 min at room temperature.
The lipofection mixture was added onto the cells and incubated at
27‡C for 5 h before replacement with culture medium. Cell lysis was
monitored by phase contrast microscopy, and culture supernatant
containing recombinant virus was harvested four days after transfec-
tion. The virus titre was analysed by plaque assay. 1U106 cells were
seeded into the wells of a 6 well plate and left to attach for 1 h. A
series of dilutions of virus were made (1032 to 1039) in Grace’s me-
dium. 1 ml of the diluted virus was added to the cell monolayers
before incubation for 1 h at room temperature. The virus inoculum
was removed and an overlay mixture of 1UGrace’s medium and 1%
(w/v) SeaPlaque agarose (Flowgen, Lich¢eld, UK) was added onto the
monolayer. Once the agarose had set, the plates were incubated at
27‡C. A neutral red overlay (0.4% (w/v) SeaPlaque agarose, 0.025%
(w/v) neutral red) was added after 6 days to assist in plaque visual-
isation. Plaques appeared as clear circles in a pink background. Initial
culture supernatants contained a virus titre of 103 to 104 pfu/ml. Virus
titre was then ampli¢ed by reinfection of Sf9 cells with a multiplicity
of infection (MOI) of between 0.01 and 0.1 pfu/cell. Culture super-
natants were harvested between 7 and 10 days post-infection, and
after two rounds of ampli¢cation, the virus titre was at least 8U107
pfu/ml. DNA isolated from recombinant virus was analysed by PCR
using primers within the translocated portion of the pFASTBAC vec-
tor and within the inserted subunit cDNAs. Products were produced
of the correct size, indicating the presence of both subunit cDNAs
within the recombinant virus DNA.
2.5. High5 cell infection and optimisation of recombinant protein
production
High titre virus was used to infect suspension-cultured High5 cells
with di¡erent MOI, and samples were collected from the cultures at
24 h time points. Both cells and culture supernatant samples were
collected, cells were extracted with a Triton X-100 extraction bu¡er
(0.1(w/v) Triton X-100, 1 mM PMSF and 0.5 Wg/ml leupeptin in TBS
(150 mM NaCl, 25 mM Tris^HCl, pH 7.40)). The cells were mixed
with a small volume of the extraction bu¡er and vortexed every 10
min for 45 min whilst incubating on ice. The mixture was centrifuged
at 1000Ug and the supernatant collected. Samples were separated by
SDS-polyacrylamide gel electrophoresis (SDS^PAGE) under non-re-
ducing conditions and transferred to nitrocellulose. The nitrocellulose
was then Western blotted using an anti-human K4 integrin mAb, 8F2,
an anti-human L1 integrin mAb, 8E3, and the mAb directed against
the epitope tag, BB2.
2.6. Puri¢cation of rsK4L1
Culture supernatant was harvested from suspension cultures of in-
fected High5 cells by centrifugation at 14 000Ug, and was precleared
by mixing with mouse IgG-Sepharose for 2 h at 4‡C. Soluble integrin
was a⁄nity puri¢ed using BB2-Sepharose (5 mg BB2 per ml of cya-
nogen bromide-activated Sepharose beads). The culture supernatant
was mixed with the Sepharose for 2 h at room temperature, and then
the beads were collected into a column and washed with ¢ve column
volumes of TBS containing 1 mM MgCl2 and 1 mM CaCl2. The
soluble protein was eluted from the column by addition of 1 mg/ml
peptide containing the sequence of the epitope tag (KEVHTNQD-
PLDK).
2.7. Solid phase ligand binding assay
Puri¢ed integrin was tested for ligand binding activity using a series
of solid phase assays. Soluble integrin was coated into half-volume
wells of a 96 well ELISA plate (Costar, High Wycombe, UK) at an
approximate concentration of 1 Wg/ml in PBS for 16 h at room
temperature. The coating solution was then removed and non-speci¢c
binding blocked by addition of 200 Wl per well of 5% (w/v) BSA in
TBS and incubated for 2 h at room temperature. A biotinylated ¢-
bronectin fragment, H120 [19], or a chimeric protein consisting of the
¢rst two domains of human VCAM-1 with a human IgG1 Fc domain
([20]; 2dVCAM-Fc) were used as ligands. Ligands were diluted in
TBS, 1 mM MnCl2, 1 mg/ml BSA (Bu¡er A) to the required concen-
tration and 50 Wl added to each well and incubated at 37‡C for 3 h.
The plate was washed three times with bu¡er A before addition of
either 50 Wl ExtrAvidin-peroxidase (1:500 dilution in bu¡er A; Sigma,
Poole, Dorset, UK), and incubated for 20 min at room temperature,
or 50 Wl Protein A-peroxidase (1:1000 dilution in bu¡er A; Sigma,
Poole, Dorset, UK) and incubated for 1 h at room temperature,
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depending on the ligand used. The plate was washed four times with
bu¡er A and 50 Wl of substrate 2,2P-azino-bis (3-ethylbenzthiazoline
6-sulphonic acid) (0.1% (w/v) ABTS in 0.1 M sodium acetate, 0.05 M
NaH2PO4, pH 5.0, 0.01% (v/v) H2O2) was added. Absorbance read-
ings were measured at 405 nm on a Dynatec MR4000 plate reader.
2.8. Identi¢cation of epitopes by sandwich ELISA
Antibodies were diluted to 10 Wg/ml in PBS and 50 Wl aliquots
coated into the half-volume assay plate overnight at 4‡C. Following
aspiration, 200 Wl/well of blocking bu¡er was added to block non-
speci¢c binding sites on the well surface, and the incubation continued
at room temperature for 2 h. Again after aspiration, 50 Wl aliquots of
soluble integrin diluted in bu¡er A were added and the plate was
incubated for 2 h at room temperature. Wells were washed three times
with bu¡er A and then 50 Wl biotinylated BB2 antibody (0.5 Wg/ml in
bu¡er A) was added per well. The plate was incubated for 1 h at room
temperature and then washed three times with bu¡er A. 100 Wl of a
1:500 dilution of ExtrAvidin-peroxidase in bu¡er A was added to the
wells, and the plate was incubated for 20 min at room temperature.
After four washes with bu¡er A, the colour reaction was developed
and measured as for the solid phase ligand binding assays.
3. Results and discussion
cDNA constructs encoding the human K4 and L1 subunits
were truncated prior to the transmembrane domains by site-
directed mutagenesis and expressed using baculovirus infec-
tion of High5 insect cells. A BB2 epitope tag was added to
the C-terminus of the K4 subunit to aid isolation by immu-
noa⁄nity chromatography. To determine the optimal condi-
tions for expression of soluble K4L1 integrin, High5 cells were
infected with recombinant virus at di¡erent MOI and the
growth medium sampled as a function of time. Samples
were analysed by SDS^PAGE under non-reducing conditions,
followed by Western-blotting with anti-integrin and anti-epi-
tope tag monoclonal antibodies. The anti-L1 monoclonal anti-
body, 8E3, recognised a protein band of molecular weight 80
kDa, the anti-K4 monoclonal antibody, 8F2, detected bands
of 110 kDa and 65 kDa (the latter probably representing the
Fig. 1. A: Schematic diagram indicating the molecular weights of
the K4 and L1 integrin subunits. The native molecular weights are
those observed with the full-length integrin. The predicted molecular
weights are those predicted from the length of the amino acid se-
quence for the soluble integrin. For the soluble K4 subunit, the pre-
dicted molecular weight also includes the 10 amino acid epitope tag
that was attached to the C-terminus of the subunit. B: SDS^PAGE
of rsK4L1. Protein was puri¢ed from High5 culture supernatant us-
ing BB2-Sepharose, analysed on a 7.5% gel under reducing condi-
tions, and stained with Coomassie Blue. The left hand lane shows
molecular weight standards with their molecular mass indicated on
the left hand side of the gel. The identity of the bands in the right
hand lane were determined by Western blotting and are indicated
on the right hand side of the gel.
Fig. 2. A: Solid phase assay of the binding of 2dVCAM-Fc (open
circles) and D40A-2dVCAM-Fc (closed circles) to rsK4L1. B: Solid
phase assay of the binding of 2dVCAM-Fc (open circles) and bio-
tinylated H/120 binding (closed circles) to rsK4L1. Error bars = stan-
dard deviation of triplicate values.
FEBS 23528 7-4-00
K. Clark et al./FEBS Letters 471 (2000) 182^186184
N-terminal cleavage product of K4), and the antibody directed
against the epitope tag, BB2, recognised bands of 110 kDa
and 43 kDa (the latter probably representing the C-terminal
cleavage product of K4; data not shown). These data are
consistent with correct expression of both integrin subunits
and with natural post-translational cleavage of the K4 subunit
(see scheme in Fig. 1A).
Optimal conditions for protein production were found to be
an MOI of 1 and a time of growth medium harvest of 72 h
(data not shown). Using these conditions, bulk cultures were
established and recombinant soluble K4L1 was puri¢ed using
immunoa⁄nity chromatography on a BB2 antibody matrix.
The yield of total puri¢ed rsK4L1 protein was in the 100^850
Wg/l range and was therefore comparable to previous reports
of soluble integrin production. The puri¢ed protein was ana-
lysed by SDS^PAGE and found to exhibit a similar banding
pattern to that observed in Western blotting experiments of
growth medium supernatant (Fig. 1B). Under reducing con-
ditions (as in Fig. 1B), the apparent molecular weight of the
L1 subunit band increased consistent with the presence of a
relatively large number of intramolecular disul¢de bonds.
Under non-reducing conditions, a proportion of the puri¢ed
protein was observed as a high molecular weight species
(s 200 kDa). This high molecular weight protein was prob-
ably due either to formation of multimeric integrin complexes
or to misfolding of the protein, as it was lost upon reduction.
To test for functional activity, the ability of puri¢ed rsK4L1
to bind to its natural ligands, VCAM-1 and ¢bronectin, was
tested using a solid phase protein^protein binding assay.
VCAM-1 was found to bind to the integrin in a dose-depen-
dent manner (Fig. 2A). Binding was speci¢c since VCAM-1
containing a point mutation, D40A, in its primary integrin
binding site produced negligible levels of binding (Fig. 2A).
In other experiments (not shown), EDTA also inhibited
VCAM-1 binding. The immobilised receptor was also able
to bind a recombinant fragment of ¢bronectin that contains
the K4L1-binding domain (H/120; 19) in a dose-dependent,
saturable manner (Fig. 2B); half-maximal binding of
VCAM-1 was obtained at V1 Wg/ml, and H/120 at V4 Wg/
ml, a similar di¡erence to that observed for the native recep-
tor [21].
To examine whether the soluble integrin was correctly
folded, the ability of a library of 15 anti-K4 and -L1 mono-
clonal antibodies to recognise the receptor was examined. A
sandwich ELISA technique was employed in which the recep-
tor was ¢rst captured by the BB2 anti-epitope tag antibody
(Fig. 3). All of the antibodies were found to bind to the
soluble integrin to varying extents, as has been observed pre-
viously for native integrin. As expected, the level of BB2 bind-
ing was reduced to the level of the control mouse and rat IgG.
Thus, the recombinant receptor is both folded and able to
bind ligand.
In summary, we have produced a rsK4L1 integrin with li-
gand binding activity and folding which resembles the native
protein. In the future, the generation of larger quantities of
receptor will permit an assessment of the product for struc-
tural and drug screening studies.
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